Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE) (HSPMOVE)

27 avril 2026 mis à jour par: Hospital de Clinicas de Porto Alegre

12-Week Strength and Functional Exercise Protocol for Treating Motor Symptoms in Individuals With Hereditary Spastic Paraplegia: Adaptive Randomized Crossover Clinical Trial

This study aims to evaluate whether a 12-week program of strength and functional exercises can improve movement and daily function in people with Hereditary Spastic Paraplegia (HSP). Participants will take part in supervised exercise sessions twice a week, delivered by videoconference, with guidance from a physiotherapist. The exercises will be tailored to each participant's abilities and goals and will focus on improving muscle strength, balance, and walking.

The study is a randomized crossover trial, meaning that all participants will experience both the exercise program and a comparison period without the intervention.

Eligible participants are individuals aged 16 to 70 years with a clinical or genetically confirmed diagnosis of HSP, who are able to walk independently (with or without assistive devices) and have stable treatment for spasticity.

Researchers will measure changes in walking ability, balance, muscle strength, and quality of life using clinical scales and functional tests. These include walking tests, mobility assessments, and questionnaires about daily activities and confidence in movement. To reduce bias, outcome assessments will be performed by an evaluator who is blinded to the participants' group allocation.

The results of this study will help determine whether a structured exercise program is safe, feasible, and effective for improving motor symptoms in people with HSP, and may support its use as part of routine care.

Aperçu de l'étude

Statut

Inscription sur invitation

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 90035-003
        • Centro de Pesquisa Clínica do Hospital de Clínicas de Porto Alegre

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Diagnosis of hereditary spastic paraplegia confirmed by genetic testing or clinical diagnosis with a positive family history
  • Age between 16 and 70 years
  • Independent ambulation, with or without assistive devices
  • Access to an electronic device (smartphone, tablet, or computer) with camera and internet connection
  • Stable therapeutic regimen for spasticity management (pharmacological and/or physiotherapy) for at least 6 months prior to enrollment

Exclusion Criteria:

  • Presence of other neurological or systemic conditions causing additional motor impairment or musculoskeletal injury limiting movement
  • Inability to perform performance outcomes even with assistive devices
  • Planned or ongoing botulinum toxin injections or surgical interventions for spasticity reduction during the 12-week intervention period

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Individualized Functional and Strength Exercise Intervention
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.
Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist. Exercises are tailored according to Goal Attainment Scaling (GAS) and baseline physical activity level. The program consists of two sessions per week and follows key training principles (individuality, overload, adaptation, specificity, continuity, reversibility, and variability) with progressive loading. The intervention focuses on improving lower limb strength and functional mobility, particularly gait, and includes balance and gait training. Sessions are scheduled with 2-3 day intervals. Each exercise includes 1-3 sets of 8-15 repetitions, with 30-60 seconds rest between sets. Training intensity ranges from 40-60% of maximal strength for sedentary participants and 50-70% for physically active participants.
Aucune intervention: No Intervention
No individualized prescription or real-time supervision will be provided during this phase. They will receive printed educational materials containing general guidance on performing strength and functional exercises.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Spastic Paraplegia Rating Scale (SPRS)
Délai: Baseline, 12 and 24 weeks
Clinician-reported outcome used to assess disease severity in hereditary spastic paraplegia (HSP). It consists of 13 items evaluating gait, lower limb strength and spasticity, joint contractures, pain, and bladder and bowel function. Total scores range from 0 to 52, with higher scores indicating greater disease severity.
Baseline, 12 and 24 weeks
Timed Up and Go Test (TUG) - maximum walking speed
Délai: Baseline, 12 and 24 weeks
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at maximum walking speed. The time to complete the task is recorded.
Baseline, 12 and 24 weeks
Goal Attainment Scaling (GAS)
Délai: Baseline, 12 and 24 weeks
individualized patient reported outcome measure used to assess the extent to which patient-specific goals are achieved during the intervention. Each participant will define four main individualized goals at baseline. Goals and expected levels of performance are defined individually for each participant and scored on a 5-point scale ranging from -2 to +2. A score of 0 represents the expected level of achievement, positive scores (+1, +2) indicate better-than-expected outcomes, and negative scores (-1, -2) indicate less-than-expected outcomes.
Baseline, 12 and 24 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
10-Meter Walk Test (10MWT) - self-selected walking speed
Délai: Baseline, 12 and 24 weeks
Performance outcome in which participants will walk at a comfortable, self-selected pace over a 10-meter distance. A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone. Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
Baseline, 12 and 24 weeks
10-Meter Walk Test (10MWT) - maximum walking speed
Délai: Baseline, 12 and 24 weeks
Performance outcome in which participants will walk at maximum walking speed over a 10-meter distance. A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone. Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.
Baseline, 12 and 24 weeks
Timed Up and Go (TUG) - self-selected walking speed
Délai: Baseline, 12 and 24 weeks
Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at at a comfortable, self-selected pace . The time to complete the task is recorded.
Baseline, 12 and 24 weeks
Falls Efficacy scale - International (Brazilian Portuguese)
Délai: Baseline, 12 and 24 weeks
Patient-reported outcome used to assess concern about falling during daily activities in community-dwelling individuals. It consists of 16 items covering functional and participation activities (e.g., sitting/standing from a chair, climbing stairs). Each item is scored from 1 (not at all concerned) to 4 (very concerned), with total scores ranging from 16 to 64. Higher scores indicate greater concern about falling.
Baseline, 12 and 24 weeks
36-Item Short Form Health Survey (SF-36) - Brazillian Portuguese
Délai: Baseline, 12 and 24 weeks
Generic, patient-reported outcome of health-related quality of life. It consists of 36 items covering multiple domains, including physical functioning, role limitations due to physical health, pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores range from 0 to 100, with higher scores indicating better overall health status.
Baseline, 12 and 24 weeks
Medical Research Council (MRC) Muscle Strength Scale
Délai: Baseline, 12 and 24 weeks
Clinician-reported outcome of muscle strength, graded from 0 (no contraction) to 5 (normal strength). Lower limb muscle groups assessed include hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.
Baseline, 12 and 24 weeks
Modified Ashworth Scale (MAS)
Délai: Baseline, 12 and 24 weeks
Clinician-reported outcome used to assess resistance to passive movement and muscle tone. It is scored on a 5-point scale from 0 (normal muscle tone) to 4 (rigid in flexion or extension). In this study, it will be applied to the hip adductor and knee flexor muscles to assess lower limb spasticity.
Baseline, 12 and 24 weeks
Patient Global Impression of Change (PGI-C)
Délai: Baseline, 12 and 24 weeks
Patient-reported outcome measuring perceived overall improvement or worsening following the intervention. It is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the patient's global assessment of change.
Baseline, 12 and 24 weeks

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Handheld Dynamometry (microFET2)
Délai: Baseline, 12 and 24 weeks
Digital health technology in which muscle strength will be assessed using a handheld dynamometer (microFET2) to measure peak force output in lower limb muscle groups including hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors. This provides an objective, quantitative measure of muscle strength (expressed in kgf) for comparison with clinical scales.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Timed Up and Go test
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Sit-to-stand, turning, and stand-to-sit times in seconds (1 decimal) will be recorded during and Timed Up and Go (TUG) test at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Cadence
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Cadence in steps/min will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Elevation Midswing, Lateral Step Variability, Circumduction
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Elevation Midswing, Lateral Step Variability, Circumduction in cm will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Gait Cycle Duration, Step Duration
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Gait Cycle Duration and Step Duration in seconds will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Gait Speed
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Gait Speed in m/s will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Stride Length
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Stride Length in meters will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM)
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM) in ° degrees will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks
Instrumented Gait Analysis (Opal Sensors System) - Double Support, Single Limb Support, Stance, Swing, Terminal Double Support
Délai: Baseline, 12 and 24 weeks
Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Double Support, Single Limb Support, Stance, Swing, Terminal Double Support in Gait Cycle Time (%) will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.
Baseline, 12 and 24 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 avril 2024

Achèvement primaire (Estimé)

1 décembre 2026

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

14 avril 2026

Première soumission répondant aux critères de contrôle qualité

27 avril 2026

Première publication (Réel)

1 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 avril 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner